1. A composition comprising a therapeutically effective amount of an isolated LukE protein or its polypeptide, an isolated LukD protein or its polypeptide, or a combination thereof, and a pharmaceutically acceptable carrier. The composition according to claim 1, characterized in that the isolated LukE protein contains the amino acid sequence of SEQ ID NO: 11.3. The composition according to claim 1, characterized in that the isolated LukE polypeptide contains amino acid residues 48-291 of SEQ ID NO: 11.4. The composition according to claim 1, characterized in that the isolated LukD protein contains the amino acid sequence of SEQ ID NO: 22.5. The composition according to claim 1, characterized in that the isolated LukD polypeptide contains amino acid residues 46-307 of SEQ ID NO: 22.6. The composition according to claim 1, characterized in that the isolated protein and its polypeptide in the composition are associated with an immunogenic carrier molecule. A composition according to claim 6, characterized in that the molecule of the immunogenic carrier is covalently or non-covalently linked to an immune protein or peptide. The composition according to claim 6, characterized in that the immunogenic carrier molecule is selected from the group consisting of bovine serum albumin, chicken egg ovalbumin, cochlear lymphocyte hemocyanin, tetanus toxoid, diphtheria toxoid, thyroglobulin, pneumococcal capsule polysaccharide, meniscus CRM 197, protein .9. The composition according to claim 1, characterized in that it further comprises one or more additional S. aureus antigens selected from the group consisting of alpha hemolysin antigen, protein A, polysaccharide antigen serotype 336, coagulase, clumping factor A, clumping factor B, Fibronectin-binding protein, Fibrinogen-binding protein,1. Композиция, содержащая терапевтически эффективное количество выделенного белка LukE или его полипептида, выделенного белка LukD или его полипептида, или их комбинацию, и фармацевтически приемл
